Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy.

Cardiac magnetic resonance Hospitalization Hypertrophic cardiomyopathy Prognosis Quality of life

Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 Nov 2020
Historique:
received: 16 04 2020
revised: 24 06 2020
accepted: 23 07 2020
pubmed: 1 8 2020
medline: 15 5 2021
entrez: 1 8 2020
Statut: ppublish

Résumé

Despite numerous studies assessing the natural history of patients with hypertrophic cardiomyopathy (HCM), there is lack of data regarding the burden of hospitalization. Aim of this study was to describe prevalence, causes and predictors of cardiovascular hospitalization in patients with HCM. We retrospectively included 253 patients with HCM undergoing first evaluation at our center. Enrolment criteria included cardiac magnetic resonance imaging (CMRI) at baseline and > 1-year follow-up. All hospital admissions were recorded during follow-up and adjudicated as acute vs elective and cardiovascular (CV) vs non-cardiovascular (non-CV). During 6.4 ± 4.0 years there were 187 hospitalizations in 92 patients (36%, at a rate of 5.7%/year). Most were CV-related (158/187,84.5%; 4.8%/year) while non-CV admissions were 29/187 (15.5%, 0.88%/year). There was a slight predominance of elective (n = 96, 58%, 2.8%/year) vs acute (n = 62, 41.8%, 2.0%/year) CV hospitalizations. Independent predictors of CV hospitalization were baseline symptoms (NYHA class II vs I: HR 2.06; 95% CI 1.24-3.43, NYHA III-IV vs I: HR 3.05; 95% CI 1.40-6.65, p = .004), indexed left atrial (LA) volume (HR 1.03; 95% CI 1.01-1.04, p < .001), and lower indexed right ventricular end-diastolic volume iRVEDV) at cardiac magnetic resonance (HR 0.99; 95% CI 0.97-0.99, p = .03). In little over 6 years, CV hospitalization was required in over one-in-three of our HCM patients, often unplanned and due to acute disease-related complications. Symptomatic status, larger LA volume and reduced iRVEDV at baseline were independently associated with CV admissions. Strategies aimed at preventing hospitalizations are an important target to reduce the burden of disease in HCM patients.

Sections du résumé

BACKGROUND BACKGROUND
Despite numerous studies assessing the natural history of patients with hypertrophic cardiomyopathy (HCM), there is lack of data regarding the burden of hospitalization. Aim of this study was to describe prevalence, causes and predictors of cardiovascular hospitalization in patients with HCM.
METHODS METHODS
We retrospectively included 253 patients with HCM undergoing first evaluation at our center. Enrolment criteria included cardiac magnetic resonance imaging (CMRI) at baseline and > 1-year follow-up. All hospital admissions were recorded during follow-up and adjudicated as acute vs elective and cardiovascular (CV) vs non-cardiovascular (non-CV).
RESULTS RESULTS
During 6.4 ± 4.0 years there were 187 hospitalizations in 92 patients (36%, at a rate of 5.7%/year). Most were CV-related (158/187,84.5%; 4.8%/year) while non-CV admissions were 29/187 (15.5%, 0.88%/year). There was a slight predominance of elective (n = 96, 58%, 2.8%/year) vs acute (n = 62, 41.8%, 2.0%/year) CV hospitalizations. Independent predictors of CV hospitalization were baseline symptoms (NYHA class II vs I: HR 2.06; 95% CI 1.24-3.43, NYHA III-IV vs I: HR 3.05; 95% CI 1.40-6.65, p = .004), indexed left atrial (LA) volume (HR 1.03; 95% CI 1.01-1.04, p < .001), and lower indexed right ventricular end-diastolic volume iRVEDV) at cardiac magnetic resonance (HR 0.99; 95% CI 0.97-0.99, p = .03).
CONCLUSIONS CONCLUSIONS
In little over 6 years, CV hospitalization was required in over one-in-three of our HCM patients, often unplanned and due to acute disease-related complications. Symptomatic status, larger LA volume and reduced iRVEDV at baseline were independently associated with CV admissions. Strategies aimed at preventing hospitalizations are an important target to reduce the burden of disease in HCM patients.

Identifiants

pubmed: 32735899
pii: S0167-5273(20)33484-7
doi: 10.1016/j.ijcard.2020.07.036
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

94-100

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors report no relationships that could be construed as a conflict of interest.

Auteurs

Michele Ciabatti (M)

Cardiomyopathy Unit, Cardiothoracic and Vascular Department, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Carlo Fumagalli (C)

Cardiomyopathy Unit, Cardiothoracic and Vascular Department, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.. Electronic address: 00.carlo@gmail.com.

Matteo Beltrami (M)

Cardiomyopathy Unit, Cardiothoracic and Vascular Department, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Elisa Vignini (E)

Cardiomyopathy Unit, Cardiothoracic and Vascular Department, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Lucia Martinese (L)

Cardiomyopathy Unit, Cardiothoracic and Vascular Department, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Alessia Tomberli (A)

Cardiomyopathy Unit, Cardiothoracic and Vascular Department, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Mattia Zampieri (M)

Cardiomyopathy Unit, Cardiothoracic and Vascular Department, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Alenya Bertini (A)

Cardiomyopathy Unit, Cardiothoracic and Vascular Department, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Gianmarco Carrassa (G)

Cardiomyopathy Unit, Cardiothoracic and Vascular Department, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Alberto Marchi (A)

Cardiomyopathy Unit, Cardiothoracic and Vascular Department, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Martina Berteotti (M)

Cardiomyopathy Unit, Cardiothoracic and Vascular Department, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Francesco Cappelli (F)

Cardiomyopathy Unit, Cardiothoracic and Vascular Department, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Leonardo Bolognese (L)

Cardiovascular Department, San Donato Hospital, Arezzo, Italy.

Maurizio Pieroni (M)

Cardiovascular Department, San Donato Hospital, Arezzo, Italy.

Iacopo Olivotto (I)

Cardiomyopathy Unit, Cardiothoracic and Vascular Department, Careggi University Hospital, Largo Brambilla 3, 50134, Florence, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH